Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BMA202203

LAG-3 mAb

BLA Filing
  • Project profile
    Project name: LAG-3 mAb
    Indications: Advanced solid tumors
    Research phase: Phase 1
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.

    1) LAG-3 belongs to the immunoglobulin (Ig) superfamily, it is a type I transmembrane protein with structural similarities to CD4.

    2) LAG-3 is extensively expressed on activated T cells and NK cells,also expressed on activated B cells and plasma cell-like dendritic cells (pDCs).

    3) LAG-3 is an inhibitory immune checkpoint for T cells, and like PD-1 and CTLA-4, LAG-3 negatively regulates the proliferation, activation, and homeostasis of T cells. It is a novel target for cancer and autoimmune disorders.

    2. Excellent preclinical efficacy:

    1) The binding activity of this LAG-3 mAb to human activated CD4 T cells is slightly higher than that of the positive control drug BH98 (Relatlimab analogue).

    2) The blocking effect on FGL1 is higher than that of BH98.

    3. Similar tumor-killing activity as Relatlimab (BH98) in vivo.

    4. The combination of LAG-3 mAb and PD-1 can synergistically enhance the anti-tumor effect, better than monotherapy.

    5. Excellent safety

    1) NOAEL= 100 mg/kg.

    2) No immunotoxicity: no ADCC activity

    3) Plasma cytokine concentrations (IFNγ, TNFα, IL6, IL1β, IL2, IL4) were not abnormally increased after mAb administration.

    4) No hemolytic effect.

  • Project Introduction

    1. Asset type: LAG-3 mAb

    2. Indication: Advanced solid tumors

    3. Research phase: Phase 1

    4. Cooperation demands:   License-out or co-development

    5. Research progress:

    1. Completed preclinical development

    2. Phase I clinical trials are ongoing to evaluate the safety, tolerability, pharmacokinetics and efficacy of candidate antibodies for advanced malignancies.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message